AbCellera Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Approximately $4 million for Q2 2026, down from $17 million in Q2 2025, primarily from research fees.

R&D Expenses: Approximately $46 million, an increase of $7 million year-over-year, reflecting investments in internal programs.

SG&A Expenses: Approximately $14 million, down from $22 million in the prior year, attributed to the conclusion of an intellectual property litigation case.

Net Loss: Roughly $55 million, compared to a loss of $35 million in Q2 2025, translating to a loss of $0.18 per share.

Cash Position: Ended the quarter with $567 million in cash and equivalents, with an additional $110 million in committed government funding, providing over $675 million in total liquidity.

2Strategic Updates and Business Highlights

Pipeline Progress:

ABCL635 for treating moderate to severe hot flashes has completed Phase I and entered Phase II, with enrollment ahead of schedule.

ABCL688 and ABCL386 are progressing towards Phase I/II studies expected in 2027.

ABCL575 Phase I trial completed dosing and is on track for Q4 readout.

T Cell Engager (TCE) Collaborations:

New partnerships with Vertex and Jazz Pharmaceuticals, adding over $110 million in upfront payments and potential for over $4 billion in total deal value.

Focus on developing multi-specific TCEs for oncology and autoimmune diseases.

Board Expansion: Welcomed two new Independent Directors with extensive biopharmaceutical experience.

3Forward Guidance and Outlook

Anticipation of positive top-line data from ABCL635, which could lead to late-stage clinical development.

Continued focus on internal programs and leveraging partnerships for TCE development.

Confidence in sufficient liquidity to fund pipeline investments for at least the next three years.

4Bad News, Challenges, or Points of Concern

Revenue Decline: Significant drop in revenue compared to the previous year raises concerns about the sustainability of current operations.

Increased Losses: The widening net loss may indicate challenges in managing expenses relative to revenue generation.

Missed Timeline: Delay in moving another program into IND-enabling activities, though progress is noted.

Regulatory Risks: Potential challenges in achieving clinically meaningful improvements in VMS severity and managing placebo responses in upcoming trials.

5Notable Q&A Insights

VMS Data Expectations: Aiming for a 20% response relative to placebo on frequency, with a focus on safety and efficacy compared to existing small molecule treatments.

Safety Differentiation: Emphasis on a clean safety profile for ABCL635, particularly regarding liver monitoring, which is a concern with current treatments.

Partnership Focus: TCE platform resources are substantial, but the majority of efforts remain on GPCR and ion channel programs.

Market Segmentation: Potential for ABCL635 as a non-hormonal option for a significant number of women, including those contraindicated for hormone therapy. Overall, AbCellera is navigating a challenging financial landscape while advancing its clinical pipeline and establishing strategic partnerships, with a cautious but optimistic outlook for upcoming data readouts and future developments.